Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
Autor: | Ibrahim Yakoub-Agha, Dirk-Jan Eikema, Silvia Montoto, Hildegard Greinix, Arnon Nagler, Mohamad Mohty, Marie Robin, Yves Chalandon, Stephen D. Robinson, Christian Chabannon, Nicolaus Kröger, Liesbeth C. de Wreede, Francesco Lanza, Stefan Schönland, Malgorzata Mikulska, Zinaida Peric, Olaf Penack, Linda Koster, Annalisa Ruggeri, Grzegorz W. Basak, Jan Styczyński |
---|---|
Přispěvatelé: | Greinix, Hildegard T, Eikema, Dirk-Jan, Koster, Linda, Penack, Olaf, Yakoub-Agha, Ibrahim, Montoto, Silvia, Chabannon, Christian, Styczynski, Jan, Nagler, Arnon, Robin, Marie, Robinson, Stephen, Chalandon, Yve, Mikulska, Malgorzata, Schönland, Stefan, Peric, Zinaida, Ruggeri, Annalisa, Lanza, Francesco, De Wreede, Liesbeth C, Mohty, Mohamad, Basak, Grzegorz W, Kröger, Nicolaus |
Rok vydání: | 2020 |
Předmět: |
Male
medicine.medical_specialty Graft vs Host Disease Disease survival Graft vs Host Disease* / prevention & control prevention Unrelated Donor Internal medicine medicine Humans Sibling Alemtuzumab ddc:616 Hematopoietic Stem Cell Transplantation* / adverse effects Hematopoietic cell business.industry Incidence (epidemiology) Hematologic Neoplasms* / complications Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease mortality Graft vs Host Disease* / etiology Transplantation stem cell diagnosi Graft-versus-host disease surgical procedures operative haploidentical bone marrow Hematologic Neoplasms Female business Unrelated Donors Calendar time |
Zdroj: | Haematologica, 107(5), 1054-1063. FERRATA STORTI FOUNDATION Haematologica, Vol. 107, No 5 (2022) pp. 1054-1063 |
ISSN: | 1592-8721 0390-6078 |
Popis: | Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P |
Databáze: | OpenAIRE |
Externí odkaz: |